Acorda Therapeutics, Inc. (ACOR) Insider Burkhard Blank Sells 11,050 Shares
Acorda Therapeutics, Inc. (NASDAQ:ACOR) insider Burkhard Blank sold 11,050 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the completion of the transaction, the insider now owns 33,150 shares of the company’s stock, valued at $680,569.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Acorda Therapeutics, Inc. (ACOR) opened at $20.80 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40. Acorda Therapeutics, Inc. has a 1 year low of $13.60 and a 1 year high of $33.00.
Acorda Therapeutics (NASDAQ:ACOR) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The company had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same period last year, the firm posted ($0.04) EPS. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. research analysts expect that Acorda Therapeutics, Inc. will post -0.07 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Oppenheimer assumed coverage on shares of Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price objective for the company. CIBC assumed coverage on shares of Acorda Therapeutics in a report on Thursday, November 9th. They issued a “market perform” rating for the company. Cantor Fitzgerald decreased their price objective on shares of Acorda Therapeutics from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, November 15th. Leerink Swann decreased their price objective on shares of Acorda Therapeutics to $18.00 and set a “market perform” rating for the company in a report on Wednesday, November 15th. Finally, J P Morgan Chase & Co decreased their price objective on shares of Acorda Therapeutics to $19.00 and set a “neutral” rating for the company in a report on Wednesday, November 15th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.47.
About Acorda Therapeutics
Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.